Quantitative analysis of (18)F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma

Por Sachpekidis, Christos, Hillengass, Jens, Goldschmidt, Hartmut, Anwar, Hoda, Haberkorn, Uwe, Dimitrakopoulou-Strauss, Antonia
Publicado no Am J Nucl Med Mol Imaging (2017)

The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma

Por Caers, Jo, Withofs, Nadia, Hillengass, Jens, Simoni, Paolo, Zamagni, Elena, Hustinx, Roland, Beguin, Yves
Publicado em 2014

Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma

Por Sachpekidis, Christos, Hillengass, Jens, Goldschmidt, Hartmut, Mosebach, Jennifer, Pan, Leyun, Schlemmer, Heinz-Peter, Haberkorn, Uwe, Dimitrakopoulou-Strauss, Antonia
Publicado no Am J Nucl Med Mol Imaging (2015)

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation

Por Mosebach, Jennifer, Shah, Sofia, Delorme, Stefan, Hielscher, Thomas, Goldschmidt, Hartmut, Schlemmer, Heinz-Peter, Schönland, Stefan, Hegenbart, Ute, Hillengass, Jens
Publicado no Haematologica (2018)

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response

Por Lehners, Nicola, Becker, Natalia, Benner, Axel, Pritsch, Maria, Löpprich, Martin, Mai, Elias Karl, Hillengass, Jens, Goldschmidt, Hartmut, Raab, Marc‐Steffen
Publicado no Cancer Med (2017)

Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma

Por Hillengass, Jens, Ayyaz, Sofia, Kilk, Kerstin, Weber, Marc-André, Hielscher, Thomas, Shah, Rajiv, Hose, Dirk, Delorme, Stefan, Goldschmidt, Hartmut, Neben, Kai
Publicado em 2012

Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study

Por Maatouk, Imad, He, Susanne, Becker, Natalia, Hummel, Manuela, Hemmer, Stefan, Hillengass, Michaela, Goldschmidt, Hartmut, Hartmann, Mechthild, Schellberg, Dieter, Herzog, Wolfgang, Hillengass, Jens
Publicado no BMJ Open (2018)

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

Por Lisenko, Katharina, Sauer, Sandra, Bruckner, Thomas, Egerer, Gerlinde, Goldschmidt, Hartmut, Hillengass, Jens, Schmier, Johann W., Shah, Sofia, Witzens-Harig, Mathias, Ho, Anthony D., Wuchter, Patrick
Publicado no BMC Cancer (2017)

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial

Por GroΔ, Jonathan P., Nattenmüller, Johanna, Hemmer, Stefan, Tichy, Diana, Krzykalla, Julia, Goldschmidt, Hartmut, Bertsch, Uta, Delorme, Stefan, Kauczor, Hans-Ulrich, Hillengass, Jens, Merz, Maximilian
Publicado no Oncotarget (2017)

Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro

Por Krämer, Isabelle, Engelhardt, Melanie, Fichtner, Sabrina, Neuber, Brigitte, Medenhoff, Sergej, Bertsch, Uta, Hillengass, Jens, Raab, Marc-Steffen, Hose, Dirk, Ho, Anthony D., Goldschmidt, Hartmut, Hundemer, Michael
Publicado no Oncoimmunology (2016)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression

Por Seckinger, Anja, MeiΔner, Tobias, Moreaux, Jérôme, Benes, Vladimir, Hillengass, Jens, Castoldi, Mirco, Zimmermann, Jürgen, Ho, Anthony D., Jauch, Anna, Goldschmidt, Hartmut, Klein, Bernard, Hose, Dirk
Publicado no Oncotarget (2015)

A systematic classification of death causes in multiple myeloma

Por Mai, Elias K., Haas, Eva-Maria, Lücke, Stephan, Löpprich, Martin, Kunz, Christina, Pritsch, Maria, Knaup-Gregori, Petra, Raab, Marc S., Schlenzka, Jana, Bertsch, Uta, Hillengass, Jens, Goldschmidt, Hartmut
Publicado no Blood Cancer J (2018)

Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smolderin...

Por Wennmann, Markus, Kintzelé, Laurent, Piraud, Marie, Menze, Bjoern H., Hielscher, Thomas, Hofmanninger, Johannes, Wagner, Barbara, Kauczor, Hans-Ulrich, Merz, Maximilian, Hillengass, Jens, Langs, Georg, Weber, Marc-André
Publicado no Oncotarget (2018)

Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients underg...

Por Neben, Kai, Jauch, Anna, Bertsch, Uta, Heiss, Christiane, Hielscher, Thomas, Seckinger, Anja, Mors, Tina, Müller, Nadine Zoe, Hillengass, Jens, Raab, Marc S., Ho, Anthony D., Hose, Dirk, Goldschmidt, Hartmut
Publicado em 2010

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance

Por Seckinger, Anja, Hillengass, Jens, Emde, Martina, Beck, Susanne, Kimmich, Christoph, Dittrich, Tobias, Hundemer, Michael, Jauch, Anna, Hegenbart, Ute, Raab, Marc-Steffen, Ho, Anthony D., Schönland, Stefan, Hose, Dirk
Publicado no Front Immunol (2018)

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma

Por Mai, Elias K., Hielscher, Thomas, Kloth, Jost K., Merz, Maximilian, Shah, Sofia, Raab, Marc S., Hillengass, Michaela, Wagner, Barbara, Jauch, Anna, Hose, Dirk, Weber, Marc-André, Delorme, Stefan, Goldschmidt, Hartmut, Hillengass, Jens
Publicado no Haematologica (2015)

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

Por Weinhold, Niels, Kirn, Desiree, Seckinger, Anja, Hielscher, Thomas, Granzow, Martin, Bertsch, Uta, Egerer, Gerlinde, Salwender, Hans, Blau, Igor W., Weisel, Katja, Hillengass, Jens, Raab, Marc S., Hose, Dirk, Goldschmidt, Hartmut, Jauch, Anna
Publicado no Haematologica (2016)

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

Por Hose, Dirk, Rème, Thierry, Hielscher, Thomas, Moreaux, Jérôme, Messner, Tobias, Seckinger, Anja, Benner, Axel, Shaughnessy, John D., Barlogie, Bart, Zhou, Yiming, Hillengass, Jens, Bertsch, Uta, Neben, Kai, Möhler, Thomas, Rossi, Jean François, Jauch, Anna, Klein, Bernard, Goldschmidt, Hartmut
Publicado em 2011

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

Por Kropff, Martin, Baylon, Honorata Giongco, Hillengass, Jens, Robak, Tadeusz, Hajek, Roman, Liebisch, Peter, Goranov, Stefan, Hulin, Cyrille, Bladé, Joan, Caravita, Tommaso, Avet-Loiseau, Herve, Moehler, Thomas M., Pattou, Claire, Lucy, Lela, Kueenburg, Elisabeth, Glasmacher, Axel, Zerbib, Robert, Facon, Thierry
Publicado em 2012

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation

Por Merz, Maximilian, Jauch, Anna, Hielscher, Thomas, Mai, Elias K., Seckinger, Anja, Hose, Dirk, Bertsch, Uta, Neben, Kai, Raab, Marc S., Salwender, Hans, Blau, Igor W., Lindemann, Hans-Walter, Schmidt-Wolf, Ingo, Scheid, Christof, Haenel, Mathias, Weisel, Katja, Goldschmidt, Hartmut, Hillengass, Jens
Publicado no Haematologica (2017)